rs180898690

Variant summary

Our verdict is Benign. Variant got -11 ACMG points: 2P and 13B. PM1BP4_StrongBP6BS1BS2

The NM_172244.3(SGCD):​c.717C>G​(p.Asp239Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000224 in 1,596,596 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 11/14 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00030 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00022 ( 2 hom. )

Consequence

SGCD
NM_172244.3 missense

Scores

14

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:7

Conservation

PhyloP100: -0.469
Variant links:
Genes affected
SGCD (HGNC:10807): (sarcoglycan delta) The protein encoded by this gene is one of the four known components of the sarcoglycan complex, which is a subcomplex of the dystrophin-glycoprotein complex (DGC). DGC forms a link between the F-actin cytoskeleton and the extracellular matrix. This protein is expressed most abundantly in skeletal and cardiac muscle. Mutations in this gene have been associated with autosomal recessive limb-girdle muscular dystrophy and dilated cardiomyopathy. Alternatively spliced transcript variants encoding distinct isoforms have been observed for this gene. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -11 ACMG points.

PM1
In a topological_domain Extracellular (size 232) in uniprot entity SGCD_HUMAN there are 7 pathogenic changes around while only 2 benign (78%) in NM_172244.3
BP4
Computational evidence support a benign effect (MetaRNN=0.0048123).
BP6
Variant 5-156757722-C-G is Benign according to our data. Variant chr5-156757722-C-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 48123.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=3, Benign=3, Uncertain_significance=1}.
BS1
Variant frequency is greater than expected in population eas. gnomad4 allele frequency = 0.000302 (46/152202) while in subpopulation EAS AF= 0.00713 (37/5186). AF 95% confidence interval is 0.00532. There are 0 homozygotes in gnomad4. There are 25 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAdExome4 at 2 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SGCDNM_000337.6 linkc.699+18C>G intron_variant Intron 8 of 8 ENST00000337851.9 NP_000328.2 Q92629-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SGCDENST00000337851.9 linkc.699+18C>G intron_variant Intron 8 of 8 1 NM_000337.6 ENSP00000338343.4 Q92629-2
SGCDENST00000435422.7 linkc.696+18C>G intron_variant Intron 7 of 7 1 ENSP00000403003.2 Q92629-1
SGCDENST00000517913.5 linkc.717C>G p.Asp239Glu missense_variant Exon 10 of 10 5 ENSP00000429378.1 Q92629-3

Frequencies

GnomAD3 genomes
AF:
0.000302
AC:
46
AN:
152084
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000145
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00712
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000852
AC:
187
AN:
219612
Hom.:
1
AF XY:
0.000849
AC XY:
100
AN XY:
117812
show subpopulations
Gnomad AFR exome
AF:
0.000152
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0113
Gnomad SAS exome
AF:
0.0000373
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000726
GnomAD4 exome
AF:
0.000216
AC:
312
AN:
1444394
Hom.:
2
Cov.:
31
AF XY:
0.000215
AC XY:
154
AN XY:
716322
show subpopulations
Gnomad4 AFR exome
AF:
0.0000905
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00702
Gnomad4 SAS exome
AF:
0.0000241
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000272
Gnomad4 OTH exome
AF:
0.000484
GnomAD4 genome
AF:
0.000302
AC:
46
AN:
152202
Hom.:
0
Cov.:
32
AF XY:
0.000336
AC XY:
25
AN XY:
74430
show subpopulations
Gnomad4 AFR
AF:
0.000144
Gnomad4 AMR
AF:
0.000131
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00713
Gnomad4 SAS
AF:
0.000207
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000188
Hom.:
0
Bravo
AF:
0.000385
ExAC
AF:
0.000572
AC:
69
Asia WGS
AF:
0.00346
AC:
12
AN:
3478

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:7
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not specified Uncertain:1Benign:2
Jun 02, 2014
Stanford Center for Inherited Cardiovascular Disease, Stanford University
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. IVS12+1 G>A (c.2489+1 G>A) in the PKP2 gene This is a variant that we can have high confidence causes ARVC. It has been reported previously in multiple patients with ARVC, from multiple ethnicities, and also in multiple unrelated individuals tested for ARVC at the testing laboratory, according to their report. It is a splice-site variant that destroys the canonical splice donor site in intron 12. It is expected to cause abnormal gene splicing, which may lead to protein truncation or absence of protein due to mRNA decay. At least 24 patients with this specific variant have been published in the literature. Gerull et al. (2004) identified it in 1 ARVC proband of Western European descent. Dalal et al. (2006) found it in 3 unrelated patients with ARVC from the Johns Hopkins registry– and den Haan et al. (2009) added 1 more North American patient to this group. Age at first symptom for these patients ranged from 22-51 years. [Reports by Dalal et al. (2009) and Tan et al. (2010) appear to refer to these same patients.] van Tintelen et al. (2006) found the variant in 3 unrelated Dutch Caucasian individuals with ARVC. Of the cohort studied, patients with this variant had the youngest age of onset (ages 17, 17, and 20). Haplotype analysis indicated that it may be a founder mutation. One patient also carried a missense variant in PKP2: p.Glu62Lys. [Bhuiyan et al. (2009) appears to refer to the same patients as the van Tintelen et al. study.] Cox et al. 2011 identified it in 6 index patients (it is unclear how many of these were in the prior paper by van Tintelen et al. 2006 from the same group); two patients also carried a missense variant in DSG2 or JUP. Two 16-year-old males in one of these families suffered sudden cardiac death. Wlodarska et al. 2008 saw it in at least one Polish patient. Fressart et al. (2010) found it in 3 unrelated individuals recruited in France and/or Switzerland. Quarta et al. (2011) saw it in one patient referred to a center in London. Palmisano et al. (2011) studied a young male athlete with aborted cardiac arrest at age 21 and his affected but asymptomatic father, who both carried this variant and also a DSC2 I109M variant. The family’s ancestry may have been from Iran. Nakajima et al. (2012) found the variant in a Japanese patient who also carried the PKP2 variant D812N (in trans, one inherited from each of his unaffected parents). He had his first cardiac syncopal event (VT) at age 11 and was diagnosed at age 20. Baskin et al. (2013) found the variant in 2 ARVC patients tested in Canada. Bao et al. (2013) found it in 4 Chinese patients with ARVC. There is only very weak segregation data available: van Tintelen et al. (2006) saw it segregate in 2 affected family members. Palmisano et al. (2011) saw it segregate in an affected father and son. In total the variant has not been seen in more than 8500 presumably unaffected individuals, including 2000 controls and ~6500 individuals from population datasets. Dalal et al. (2006) did not find it in 200 controls (ancestry not specified); van Tintelen et al. (2006), 150 Caucasian controls; Wlodarska et al. (2008), 100 Caucasian controls; Fressart et al. (2010), 300 Caucasian controls; Cox et al. (2011), 200 Dutch Caucasian controls; Quarta et al. (2011), 300 ethnically-matched controls; Nakajima et al. (2012), 80 Japanese controls; Baskin et al. (2013), 427 controls; Bao et al. (2013), 300 Chinese(?) controls. It is not seen in the NHLBI Exome Sequencing Project (ESP) dataset, which currently includes variant calls on ~4300 Caucasian and ~2200 African American individuals. None of these individuals are ancestry-matched to our patient, whose ancestry is Chinese. The -

Nov 03, 2017
Eurofins Ntd Llc (ga)
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 06, 2014
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

p.Asp239Glu in exon 8 of SGCD: This variant is not expected to have clinical sig nificance because has been reported in multiple Asian individuals with various c ardiomyopathies and did not segregate with disease in 2 affected relatives in on e family. In addition, it has been identified in 0.3% (2/572) of Asian chromosom es by the 1000 Genomes Project (dbSNP rs180898690) and in 1.5% (54/3652) East As ian chromosomes by the Exome Aggregation Consortium (ExAC; http://exac.broadinst itute.org). -

not provided Uncertain:1Benign:2
Jun 24, 2013
Biesecker Lab/Clinical Genomics Section, National Institutes of Health
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: research

- -

Sep 12, 2017
Athena Diagnostics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 27, 2018
GeneDx
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

See Variant Classification Assertion Criteria. -

SGCD-related disorder Benign:1
Aug 20, 2024
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Autosomal recessive limb-girdle muscular dystrophy type 2F Benign:1
Jan 23, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Autosomal recessive limb-girdle muscular dystrophy type 2F;C1847667:Dilated cardiomyopathy 1L Benign:1
Nov 19, 2017
Counsyl
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
-0.69
T
BayesDel_noAF
Benign
-0.76
CADD
Benign
5.9
DANN
Benign
0.15
Eigen
Benign
-0.99
Eigen_PC
Benign
-1.0
FATHMM_MKL
Benign
0.065
N
LIST_S2
Benign
0.20
T
MetaRNN
Benign
0.0048
T
MetaSVM
Benign
-1.0
T
PROVEAN
Benign
0.19
N
REVEL
Benign
0.068
Sift
Benign
0.059
T
Sift4G
Benign
0.12
T
Polyphen
0.0080
B
Vest4
0.076
MutPred
0.24
Gain of sheet (P = 0.0221);
MVP
0.54
ClinPred
0.0080
T
GERP RS
2.3

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs180898690; hg19: chr5-156184733; API